University of Minnesota

New York Blood Center, Inc.

Marc Kevin Jenkins

Lanying Du

Wanbo Tai

Sung-Wook Hong

Thamotharampillai Dileepan

Jian Shang

Justin J Taylor

Yushun Wan

Brian T Fife

Frank Jonathan Lee

Deepali Malhotra

Justin A Spanier

Qibin Geng

The present disclosure provides variant major histocompatibility complex class II (MHCII) beta chains, as well as heterodimers and multimers including MHCII alpha chains and the variant MHCII beta chains. Also provided by the present disclosure are nucleic acids, expression cassettes, and expression vectors encoding the MHCII beta chains. The heterodimers and multimers of the present disclosure have a higher affinity for CD4 co-receptors than comparable reagents including wild type MHCII beta chains, and therefore are advantageous for use in methods of phenotyping or activating CD4T cells.

Co-receptor affinity enhanced major histocompatibility class II molecules

The present disclosure provides virus like nanoparticles (VLPs), which are capable of displaying multiple copies of a SARS-CoV-2 antigen, for eliciting protective immunity against a SARS-CoV-2 infection, as well as polypeptides, compositions and methods thereof.

Virus like nanoparticle compositions and methods thereof

Phycoerythrin (PE) and peptide:MHCII (p:MHCII) reactive monoclonal antibodies; methods to generate monoclonal antibodies including, for example, peptide:MHC (p:MHC) reactive monoclonal antibodies; compositions including monoclonal antibodies; and uses thereof.

Monoclonal antibodies directed to peptide in the context of MHC and methods of making and using monoclonal antibodies

Growing community of inventors

Minneapolis, MN, United States of America

Marc Kevin Jenkins